Joel Beatty
Stock Analyst at Baird
(4.52)
# 284
Out of 5,130 analysts
202
Total ratings
49.08%
Success rate
31.06%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $72 → $47 | $22.51 | +108.80% | 5 | Dec 30, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Outperform | $16 → $14 | $9.30 | +50.54% | 3 | Nov 24, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $160 → $209 | $161.13 | +29.71% | 5 | Nov 18, 2025 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $145 → $125 | $87.02 | +43.65% | 9 | Nov 6, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Outperform | $10 → $19 | $12.21 | +55.61% | 5 | Oct 16, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $10 → $7 | $3.33 | +110.21% | 3 | Sep 30, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $50 → $67 | $38.19 | +75.44% | 3 | Sep 9, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $4 → $6 | $2.07 | +189.86% | 5 | Aug 13, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $7 → $9 | $35.35 | -74.54% | 6 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $26.78 | +15.76% | 4 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $24 | $17.92 | +33.93% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $680 | $788.49 | -13.76% | 7 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $29 | $17.08 | +69.79% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $66 | $77.53 | -14.87% | 15 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $169.38 | -4.36% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $29.66 | +38.23% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $16 | $13.84 | +15.61% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $288.45 | -74.69% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $22.72 | +40.85% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $86.75 | -13.54% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $2.95 | +137.29% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $58.95 | +10.26% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $540 → $240 | $1.15 | +20,769.57% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.34 | +235.82% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $19.30 | +29.53% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $21.00 | +33.33% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $1.49 | +973.83% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $1.59 | -21.38% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.32 | +3,233.33% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $64.56 | -10.16% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $37.36 | -35.76% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $6.78 | +165.49% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $3.08 | +94.81% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $5.85 | +378.63% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $398.29 | -56.06% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $7.33 | +91.00% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $23.83 | +353.21% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $80.30 | -2.86% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $17.01 | +487.89% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $15.82 | +658.53% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $4.00 | +11,150.00% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.88 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $7.27 | +106.33% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2,400 → $1,200 | $0.49 | +247,220.69% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $9.41 | +101.91% | 3 | Nov 10, 2017 |
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $72 → $47
Current: $22.51
Upside: +108.80%
Contineum Therapeutics
Nov 24, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $9.30
Upside: +50.54%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Outperform
Price Target: $160 → $209
Current: $161.13
Upside: +29.71%
e.l.f. Beauty
Nov 6, 2025
Maintains: Outperform
Price Target: $145 → $125
Current: $87.02
Upside: +43.65%
Amylyx Pharmaceuticals
Oct 16, 2025
Maintains: Outperform
Price Target: $10 → $19
Current: $12.21
Upside: +55.61%
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $10 → $7
Current: $3.33
Upside: +110.21%
Dianthus Therapeutics
Sep 9, 2025
Maintains: Outperform
Price Target: $50 → $67
Current: $38.19
Upside: +75.44%
Editas Medicine
Aug 13, 2025
Maintains: Outperform
Price Target: $4 → $6
Current: $2.07
Upside: +189.86%
Cogent Biosciences
Jul 8, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $35.35
Upside: -74.54%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $26.78
Upside: +15.76%
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $17.92
Upside: +33.93%
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $788.49
Upside: -13.76%
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $17.08
Upside: +69.79%
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $77.53
Upside: -14.87%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $169.38
Upside: -4.36%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $29.66
Upside: +38.23%
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $13.84
Upside: +15.61%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $288.45
Upside: -74.69%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $22.72
Upside: +40.85%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $86.75
Upside: -13.54%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $2.95
Upside: +137.29%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $58.95
Upside: +10.26%
May 15, 2024
Maintains: Outperform
Price Target: $540 → $240
Current: $1.15
Upside: +20,769.57%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.34
Upside: +235.82%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $19.30
Upside: +29.53%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $21.00
Upside: +33.33%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $1.49
Upside: +973.83%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $1.59
Upside: -21.38%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.32
Upside: +3,233.33%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $64.56
Upside: -10.16%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $37.36
Upside: -35.76%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $6.78
Upside: +165.49%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $3.08
Upside: +94.81%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $5.85
Upside: +378.63%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $398.29
Upside: -56.06%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $7.33
Upside: +91.00%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $23.83
Upside: +353.21%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $80.30
Upside: -2.86%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $17.01
Upside: +487.89%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $15.82
Upside: +658.53%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $4.00
Upside: +11,150.00%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.88
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $7.27
Upside: +106.33%
Aug 17, 2018
Maintains: Neutral
Price Target: $2,400 → $1,200
Current: $0.49
Upside: +247,220.69%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $9.41
Upside: +101.91%